AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01996852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Constriction Device
Description: The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call.
Study NCT01996852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Constriction Device
Description: The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call.
Study NCT02349321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skhokho Supporting Success for Schools
Description: All information describing each facet of the intervention are included in the arm/group descriptions.
Study NCT02349321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skhokho Supporting Success for Families
Description: All information describing each facet of the intervention are included in the arm/group descriptions.
Study NCT02034669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminectomy
Description: surgical laminectomy with glial scar resection
Study NCT02034669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradural space
Description: ADSCs injection into Intradural space at damage site
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: Capsule, oral, 100 mg, once daily, 7 days
Study NCT02034669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrathecal
Description: ADSCs Intrathecal into lumbar puncture
Study NCT02034669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous
Description: ADSCs intravenous
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Capsule, oral, 300 mg, once daily, 10 days
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Capsule, oral, 300 mg, once daily, 7 days
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Description: Oral, 10 days
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Description: Oral, 7 days
Study NCT03567304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg
Description: Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
Study NCT03767998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMST
Description: 5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
Study NCT03489850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
Study NCT03489850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is matched to ibudilast active medication.
Study NCT02055170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride 5mg oral daily
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Famotidine (FAM)
Description: Tablet, oral, 20 mg, twice daily, 7 days
Study NCT03320889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
Study NCT03627143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KTI activities
Description: The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance
Study NCT02671175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Famotidine (FAM)
Description: Tablet, oral, 40 mg, twice daily, 7 days
Study NCT03122236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation of Standard Walking
Description: Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
Study NCT00501462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK189075
Description: single 250 mg dose of drug
Study NCT02354261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-Itraconazole
Description: Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
Study NCT00375505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00375505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02053922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
Study NCT02053922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
Study NCT02053922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
Study NCT03879616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Enhanced Reminder
Description: This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure.
Study NCT03879616 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: An Enhanced Reminder
Description: This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure.
Study NCT00568607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFO, VP-16, DDP, DXM
Description: DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Study NCT04134169 — intervention group
Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study NCT03454945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibramycin
Description: Antibiotic
Study NCT03454945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibramycin
Description: Antibiotic
Study NCT03454945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: UVA+Psoralen
Study NCT03454945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: UVA+Psoralen
Study NCT00626886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge
Description: collagen; Bupivacaine hydrocholoride
Study NCT00626886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo collagen sponge
Description: collagen
Study NCT04695470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and Sintilimab
Description: fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w
Study NCT01104545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Study NCT05060198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
Study NCT05060198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
Study NCT03499769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural orifice
Description: laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
Study NCT04016103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MY01 - Continuous Compartmental Pressure Monitor
Description: Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
Study NCT01104545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Study NCT00771927 — intervention group
Intervention type: DRUG
Intervention: Lacosamide
Description: Vimpat was used as per site routine practices, and in-line with the marketing authorization.
Study NCT01171014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
Study NCT02671175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dihydroartemisinin-piperaquine placebo
Description: Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Study NCT02871297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Study NCT00541931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dietary Supplement: LifePak Nano
Description: Daily use
Study NCT01559337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve transfer
Description: the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
Study NCT00038090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg capsules by mouth daily each evening
Study NCT00038090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
Study NCT03122236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation of Complex Walking
Description: Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
Study NCT01229007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: 1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
Study NCT03528876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX and FOLFIRI
Description: a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
Study NCT03085134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test infant formula with HMOs
Description: Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
Study NCT03085134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control infant formula without HMOs
Description: Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
Study NCT01171014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
Study NCT01171014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day for 14 days
Study NCT02674113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia bupivacaine
Description: a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
Study NCT02674113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regional anesthesia placebo
Description: subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
Study NCT03069742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
Study NCT03069742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNAV
Description: Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
Study NCT04389710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
Study NCT01632592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
Study NCT01632592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given by injection 2mg subcutaneously daily
Study NCT04893044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all.
Study NCT00323427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Living Well with Hearing Loss Workshop
Description: Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
Study NCT03122236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (Sham tDCS)
Description: tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.
Study NCT03122236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation (Active tDCS)
Description: tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.
Study NCT00942487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebilet
Description: Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
Study NCT00942487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corvitol
Description: Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
Study NCT01311622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
Study NCT01311622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: 2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
Study NCT04264013 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
Study NCT04264013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise plus diet (egg)
Description: Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
Study NCT02369484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: 40mg p.o./ day until documented progression or unacceptable toxicity
Study NCT00538759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
Study NCT00538759 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study NCT02809794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare CPAP Device
Description: Fisher \& Paykel Healthcare CPAP Device
Study NCT04977700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
Study NCT03610594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kalaripayattu
Description: Combination of Exercise, breathing, meditation, combat practices